MAHONEY DAVID L sold $1.7M of CORT (indirect holdings)
MAHONEY DAVID L sold 20,000 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at $84.53 ($1.69M total) on 2026-06-17.
How this was made
The 30-second read
Why it matters
The newest fact is the reported sale of 20,000 shares (~$1.69M) on 2026-06-17, with holdings after the transaction at 26,147 shares and no pre-arranged 10b5-1 plan.
Market read
Traders may monitor for follow-on insider activity, but this filing alone is not a fundamental catalyst.
What to watch
No context on total holdings, tax events, or whether other insiders are selling/buying around the same period; without that, the signal is weak.
Background
SEC Form 4 insider transaction disclosure for Corcept Therapeutics (director David L. Mahoney).
Ticker impact
Corcept Therapeutics director David L. Mahoney filed a Form 4 reporting an indirect open-market sale of 20,000 shares at $84.5253 on 2026-06-17.
Low likelihood of a sustained price move; any impact would be short-lived unless accompanied by broader insider selling or new company-specific news.
The filing is a Form 4 insider transaction with no 10b5-1 plan and a disclosed sale size (~$1.69M). However, insider sales are common and the article provides no new operational/regulatory/financial catalyst.
Market effects
Minimal; this is company-specific insider activity with no sector-wide signal provided.
None indicated.
None indicated.
Counterpoint
The sale is indirect and may reflect diversification/liquidity needs rather than a bearish view; absence of a 10b5-1 plan does not necessarily imply negative information.
Key entities
- issuerCORCEPT THERAPEUTICS INC
Subject of the Form 4 insider transaction; director reported an indirect open-market sale.
- insiderMAHONEY DAVID L
Director who reported the sale; transaction code S (open-market sale).
